SCHEMBL2437883

SCHEMBL2437883

CCOC(=O)C1(COc2ccc(-c3ccc(Cl)cn3)cc2)CCN(C(=O)c2ccc(OC)cc2)C1

nearest known ligand 0.55

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PTGER4 P35408 1/20 0.55
PTGER2 P43116 1/20 0.55
PTGDR Q13258 1/20 0.55
MEN1 O00255 6/20 0.45
KMT2A Q03164 6/20 0.45
ALDH1A1 P00352 6/20 0.44
PKM P14618 2/20 0.44
MAPT P10636 2/20 0.44
L3MBTL1 Q9Y468 2/20 0.44
LMNA P02545 1/20 0.44
P4HB P07237 1/20 0.43
DRD2 P14416 2/20 0.43
KCNA5 P22460 1/20 0.43
DRD3 P35462 1/20 0.43
HSD17B10 Q99714 2/20 0.42
HPGD P15428 1/20 0.42
NPSR1 Q6W5P4 2/20 0.42
GAA P10253 1/20 0.41
POLB P06746 1/20 0.41
USP2 O75604 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2436344 0.96 PTGER4 (0.49) PTGER4PTGER2PTGDRMEN1KMT2A
SCHEMBL2438789 0.95 PTGER4 (0.53) PTGER4PTGER2PTGDRMEN1KMT2A
SCHEMBL2441662 0.92 PTGER2 (0.46) PTGER4PTGER2PTGDRMEN1KMT2A
SCHEMBL2442842 0.91 PTGER4 (0.47) PTGER4PTGER2PTGDRMEN1KMT2A
SCHEMBL2440010 0.91 PTGER4 (0.57) PTGER4PTGER2PTGDRMEN1KMT2A
SCHEMBL2438627 0.88 PTGER4 (0.49) PTGER4PTGER2PTGDRMEN1KMT2A
SCHEMBL2434756 0.87 PTGER2 (0.44) PTGER4PTGER2PTGDRMEN1KMT2A
SCHEMBL2440024 0.87 NPSR1 (0.43) PTGER4PTGER2PTGDRMEN1KMT2A
SCHEMBL3322222 0.87 PTGER4 (0.50) PTGER4PTGER2PTGDRMEN1KMT2A
SCHEMBL2434921 0.84 PTGER2 (0.62) PTGER4PTGER2PTGDRMEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8278343-B2 Pyrrolidines PFIZER INC. (US) 2012-10-02 US disclosed
US-8278343-B2 Pyrrolidines PFIZER INC. (US) 2012-10-02 US disclosed
US-8278343-B2 Pyrrolidines PFIZER INC. (US) 2012-10-02 US disclosed
EP-2364296-A1 PYRROLIDINES Pfizer Limited (GB) 2011-09-14 EP disclosed
WO-2010052625-A1 PYRROLIDINES PFIZER LIMITED (GB) 2010-05-14 WO disclosed
WO-2010052625-A1 PYRROLIDINES PFIZER LIMITED (GB) 2010-05-14 WO disclosed
US-20100120793-A1 Pyrrolidines PFIZER ANIMAL HEALTH UK 1 LIMITED (GB) 2010-05-13 US disclosed
US-20100120793-A1 Pyrrolidines PFIZER ANIMAL HEALTH UK 1 LIMITED (GB) 2010-05-13 US disclosed
US-20100120793-A1 Pyrrolidines PFIZER ANIMAL HEALTH UK 1 LIMITED (GB) 2010-05-13 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100120793-A1 Pyrrolidines PTGER2, PTGDR2, PTGES2 PTGER4 11/4885PTGER2 1/4885PTGDR 10/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.